ReviewJournal of neuro-oncology2020
Boron neutron capture therapy for malignant brain tumors.
Review in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 81 citations in OpenAlex.
- Review
- Carboranyl-Curcuminoids for the Neutron Capture-Based Treatment of Amyloid Aggregates in Alzheimer's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrating measurement and simulation for evaluation of patient-specific whole-body dosimetry in clinical BNCT.Medical physics · 2026Article
- Uptakes of boronophenylalanine in theIBRO neuroscience reports · 2025Article
- Dual tumor control and neuroprotective efficacy of Boron Neutron Capture Therapy in orthotopic mouse glioma model.Journal of neuro-oncology · 2025Article
- Review
- Boron neutron capture therapy in the context of tumor heterogeneity: progress, challenges, and future perspectives.Frontiers in oncology · 2025Review
- The Level of Circulating M-MDSCs as an Indicator for the Therapeutic Outcome of BNCT in End-Stage Malignant Brain Tumor Patients.International journal of particle therapy · 2024Article
- Radiotherapeutic advances in the management of glioblastoma.Journal of neuro-oncology · 2024Review
- Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT.Cancer communications (London, England) · 2024Review
- Advances in Chitosan-based Drug Delivery Systems in Melanoma: A Narrative Review.Current medicinal chemistry · 2024Review
- The current status and novel advances of boron neutron capture therapy clinical trials.American journal of cancer research · 2024Review
- Recent progress of nano-drugs in neutron capture therapy.Theranostics · 2024Review
- Targeted Boron Neutron Capture Therapy Using Polymalic Acid Derived Nano-Boron to Treat Glioblastoma.Journal of oncology research and therapy · 2024Article
- Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT).Pharmaceutics · 2023Review
- Review
- Nanostructured boron agents for boron neutron capture therapy: a review of recent patents.Medical review (2021) · 2023Review
- Article
- Development of optimization method for uniform dose distribution on superficial tumor in an accelerator-based boron neutron capture therapy system.Journal of radiation research · 2023Article
- Advances in Boron Neutron Capture Therapy (BNCT) for Recurrent Intracranial Meningioma.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoron neutron capture therapy (BNCT) is tumor-selective particle radiation therapy that depends on the nuclear capture and fission reactions. These reactions occur when a non-radioactive boron isotope ( CLINICAL
resultsThese clinical applications of BNCT have been performed with reactor-based neutron sources over the past decades. We also applied reactor-based BNCT for 58 newly diagnosed glioblastomas and 68 recurrent malignant gliomas including 52 glioblastomas. In this review article, we summarize the clinical results from the literature concerning BNCT for these high-grade gliomas (including our research). We also applied reactor-based BNCT for 46 cases of recurrent and refractory high-grade meningiomas, and some of the results will be presented herein. FUTURE PROSPECTS: In Japan, neutron sources have been shifted from reactors to accelerators. Phase 1 and 2 clinical trials have been performed for recurrent malignant gliomas using accelerator-based neutron sources, and now fortunately, a cyclotron-based neutron generator has been approved as a medical device by Japanese regulatory authority, as the world's first accelerator-based BNCT system for medical use. We also discuss the future prospects of accelerator-based BNCT in hospitals as therapy for malignant brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.